Seres Therapeutics Inc [MCRB] stock is trading at $1.03, up 7.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MCRB shares have gain 28.65% over the last week, with a monthly amount glided 12.61%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, JP Morgan started tracking the stock with Neutral rating on April 21, 2023, and set its price target to $7. On July 23, 2021, downgrade downgraded it’s rating to Sell and revised its price target to $7 on the stock. Chardan Capital Markets upgraded its rating to a Buy but $30 remained the price target by the analyst firm on March 05, 2021. Chardan Capital Markets downgraded its rating to Neutral for this stock on September 18, 2020, and downed its price target to $27.50. In a note dated August 18, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $40 on this stock.
Seres Therapeutics Inc [MCRB] stock has fluctuated between $0.54 and $3.29 over the past year. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $1.03 at the most recent close of the market. An investor can expect a potential return of 21.36% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
Seres Therapeutics Inc [NASDAQ:MCRB] reported sales of 0.37M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -19.19% with Operating Profit Margin at -434.57%, Pretax Profit Margin comes in at -433.44%, and Net Profit Margin reading is -433.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is 3.14 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9239 points at the first support level, and at 0.8177 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1231, and for the 2nd resistance point, it is at 1.2161.
Ratios To Look Out For
For context, Seres Therapeutics Inc’s Current Ratio is 1.38. As well, the Quick Ratio is 0.89, while the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 424.19.
Transactions by insiders
Recent insider trading involved DesRosier Thomas, Chief Legal Officer and EVP, that happened on Aug 16 ’24 when 873.0 shares were sold., von Moltke Lisa completed a deal on Aug 16 ’24 to sell 973.0 shares. Meanwhile, Henn Matthew R. sold 923.0 shares on Aug 16 ’24.
